Sarepta Therapeutics Inc (NASDAQ:SRPT)’s share price gapped up prior to trading on Tuesday after Credit Suisse Group raised their price target on the stock from $81.00 to $100.00. The stock had previously closed at $81.84, but opened at $79.10. Credit Suisse Group currently has an outperform rating on the stock. Sarepta Therapeutics shares last traded at $81.22, with a volume of 1276994 shares traded.
Other equities analysts also recently issued research reports about the stock. Leerink Swann reiterated a “positive” rating and issued a $92.00 price target (up previously from $79.00) on shares of Sarepta Therapeutics in a report on Tuesday. BidaskClub downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 10th. Zacks Investment Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. UBS Group reiterated an “outperform” rating and issued a $56.51 price target (down previously from $76.00) on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Finally, HC Wainwright set a $75.00 price target on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics presently has an average rating of “Buy” and an average target price of $72.17.
Institutional investors have recently added to or reduced their stakes in the stock. 361 Capital LLC acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at $1,914,000. Janney Montgomery Scott LLC acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at $474,000. Jennison Associates LLC grew its stake in Sarepta Therapeutics by 0.6% in the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after acquiring an additional 6,357 shares during the period. Hikari Power Ltd acquired a new stake in Sarepta Therapeutics in the 3rd quarter valued at $1,134,000. Finally, Oppenheimer & Co. Inc. grew its stake in Sarepta Therapeutics by 53.0% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after acquiring an additional 11,639 shares during the period. 85.14% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The company had revenue of $57.30 million during the quarter, compared to analyst estimates of $57.33 million. During the same period in the prior year, the business posted ($0.71) EPS. Sarepta Therapeutics’s revenue was up 961.1% compared to the same quarter last year. research analysts forecast that Sarepta Therapeutics Inc will post -1.18 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3260444/sarepta-therapeutics-srpt-shares-gap-up-on-analyst-upgrade.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.